Breast Cancer Research Review, Issue 79
In this issue:
Trastuzumab deruxtecan in HER2-low metastatic breast cancer
First-line ribociclib 600 vs. 400mg in hormone receptor+, HER2– advanced breast cancer
Adjuvant carboplatin-intensified chemotherapy in high-risk, early-stage, triple-negative breast cancer
Outcomes of anastrozole, letrozole and exemestane in postmenopausal breast cancer
Adjuvant chemotherapy for hormone receptor+, HER2– breast cancer
Fear and medical misinformation in breast cancer
Pembrolizumab extended-interval dosing in breast cancer
First-line ribociclib + letrozole in elderly hormone receptor+, HER2– advanced breast cancer
Predicting heart failure and cardiomyopathy after breast cancer treatment
ARX788 for HER2+ breast cancer and brain metastases
Expert contributor
Dr Hilary Martin
Dr Hilary Martin, is a medical oncologist at Fiona Stanley Hospital Perth subspecialising in breast cancer. Her initial oncology training was undertaken in South Australia. She subsequently worked as a breast unit fellow at the Royal Marsden Hospital, London, and also as a clinical fellow at Royal Perth Hospital. She has a Masters of Public […]
Latest Publications and Videos
Stay up to date with our latest clinical information.
Explore Research Review Publications and Videos
Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry.
Terms and Conditions
Website terms of use
By using our website, you agree to follow these terms and conditions.
Privacy policy
We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms.
Copyright and use of website content
The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use.
You cannot: copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission.
Links to third-party websites
The Research Review website may link to third-party websites for your convenience. However:
We do not endorse or approve their products, services, or actions.
We are not responsible for their content or how they operate.
There is no formal partnership between us and third parties unless we clearly state otherwise.
Disclaimer and limitation of liability
We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date.
To the fullest extent allowed by law, we are not responsible for:
Any loss, damage, or costs you may suffer from using (or being unable to use) our website.
Any decisions you make based on the information provided.
Any business losses, such as lost profits, lost data, or business interruptions.
Governing law
These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.